Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.

Inclusion Criteria:

• Age ≥ 18 years of age.
• Have an ECOG Performance Status of ≤ 2.
• No evidence of distant metastasis on imaging.
• Histologic or cytologic proven adenocarcinoma of the pancreas.
• Providing informed consent prior to enrollment in the trial.

Exclusion Criteria:

• Failure to obtain additional core needle biopsies for generating PDTs.
• Females who are pregnant or plan to become pregnant.